Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Louis Williams"'
Autor:
Danai Dima, Al-Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract The presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM patients who were treated with standard-of-care (SOC) ch
Externí odkaz:
https://doaj.org/article/4d4e0e6e0fe64208a7cce810ec77ca4d
Autor:
Muhammad Hamza Habib, Yun Kyoung Ryu Tiger, Danai Dima, Mathias Schlögl, Alexandra McDonald, Sandra Mazzoni, Jack Khouri, Louis Williams, Faiz Anwer, Shahzad Raza
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 7, p 1991 (2024)
Light chain amyloidosis is a plasma–cell disorder with a poor prognosis. It is a progressive condition, causing worsening pain, disability, and life-limiting complications involving multiple organ systems. The medical regimen can be complex, includ
Externí odkaz:
https://doaj.org/article/ac8229db53c24a93935320332a4076be
Autor:
Omar Nadeem, Sikander Ailawadhi, Jack Khouri, Louis Williams, Donna Catamero, Kathryn Maples, Jesús Berdeja
Publikováno v:
Cancers, Vol 16, Iss 5, p 1023 (2024)
Multi-agent regimens incorporating immunomodulatory (IMiD®) agents such as thalidomide, lenalidomide, and pomalidomide have become the preferred standard of care for the treatment of patients with multiple myeloma (MM), resulting in improved surviva
Externí odkaz:
https://doaj.org/article/3a0a46aa916e429d8166e8d35d776112
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/7daf15cc55064c6a9b76d6dbaf1dab43
Autor:
Hussein Awada MD, Adel Hajj Ali MD, Faiz Anwer MD, Raza Shahzad MD, Sandra Mazzoni DO, Louis Williams MD, Chakra Chaulagain MD, Betty Hamilton MD, Craig Sauter MD, Jack Khouri MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy i
Externí odkaz:
https://doaj.org/article/3e1c320b5af24613aca67d97e4fb0850
Autor:
Cody Ashby, Eileen M. Boyle, Michael A. Bauer, Aneta Mikulasova, Christopher P. Wardell, Louis Williams, Ariel Siegel, Patrick Blaney, Marc Braunstein, David Kaminetsky, Jonathan Keats, Francesco Maura, Ola Landgren, Brian A. Walker, Faith E. Davies, Gareth J. Morgan
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 5, Pp 1-9 (2022)
Abstract Deciphering genomic architecture is key to identifying novel disease drivers and understanding the mechanisms underlying myeloma initiation and progression. In this work, using the CoMMpass dataset, we show that structural variants (SV) occu
Externí odkaz:
https://doaj.org/article/bfe0c5a7378449fc9275731e9baa6d54
Autor:
Hussein Ghamlouch, Eileen M. Boyle, Patrick Blaney, Yubao Wang, Jinyoung Choi, Louis Williams, Michael Bauer, Daniel Auclair, Benedetto Bruno, Brian A. Walker, Faith E. Davies, Gareth J. Morgan
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-23 (2021)
Abstract Despite improvements in outcome, 15-25% of newly diagnosed multiple myeloma (MM) patients have treatment resistant high-risk (HR) disease with a poor survival. The lack of a genetic basis for HR has focused attention on the role played by ep
Externí odkaz:
https://doaj.org/article/461e41ddf12c4094a177bd08ae6ef5ec
Autor:
Danai Dima, Fauzia Ullah, Sandra Mazzoni, Louis Williams, Beth Faiman, Austin Kurkowski, Chakra Chaulagain, Shahzad Raza, Christy Samaras, Jason Valent, Jack Khouri, Faiz Anwer
Publikováno v:
Cancers, Vol 15, Iss 7, p 2160 (2023)
Multiple myeloma (MM) is the second most common hematologic malignancy in adults worldwide. Over the past few years, major therapeutic advances have improved progression-free and overall survival, as well as quality of life. Despite this recent progr
Externí odkaz:
https://doaj.org/article/47cc387c6ced4d599016af668fad52ee
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 2, Iss 4 (2021)
The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 19 drug approvals and at least eight different active
Externí odkaz:
https://doaj.org/article/c58c94026e9649019d0f06e2f35dfc4f
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Following allogeneic blood and marrow transplantation (BMT), graft-versus-host disease (GvHD) continues to represent a significant cause of treatment failure, despite the routine use of conventional, mainly calcineurin inhibitor-based prophylaxis. Re
Externí odkaz:
https://doaj.org/article/100d22a9d67d4ab8a0e8d3dc7b19b766